Gérard Dahan Joins Determine, Inc. as Chief Marketing Officer and SVP of EMEA
CARMEL, Ind., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Determine, Inc. (NASDAQ:DTRM), the pioneering leader in global Source-to-Pay and Enterprise Contract Lifecycle Management (ECLM) Cloud Platform solutions, announced today that Gérard Dahan has been named to the newly created position of Chief Marketing Officer and Senior Vice President of EMEA.
A veteran executive in the Procurement Solutions industry, Mr. Dahan has 25 years of experience in leadership, sales management, business development and strategic marketing with global technology and services companies including Ivalua, BravoSolution, Ariba, Intel and IBM.
"We are so pleased and excited to add a leader with Gérard's depth of experience and industry knowledge to the Determine executive bench. We are consistently breaking new ground with the Determine Cloud Platform, and Gérard's expertise significantly increases our ability to effectively communicate its many advantages. His international background will be instrumental in delivering significant new opportunities into our pipeline on a global basis."
- Patrick Stakenas, President and CEO, Determine, Inc.
Mr. Dahan is a results-oriented and award-winning marketer with a long track record of leading high-performance teams, successfully increasing market share and leveraging partnership programs. An industry veteran, he is known for his ability to nurture and grow a business, evaluate opportunities and risks, and deliver innovative new solutions.
"I have been lucky in my career to always be at companies that were at an inflection point, that threshold of changing how things are done for good. I see that inflection point at Determine right now. The Determine Cloud Platform is absolutely going to change the way people and organizations work. None of the other leading industry providers I spoke to during my search are effectively doing this. The strength of the management team, the people and the products is outstanding. I'm very excited to be here, to be a part of making success happen."
- Gérard Dahan, Chief Marketing Officer, SVP EMEA, Determine, Inc.
About Determine, Inc.
Determine, Inc. (NASDAQ:DTRM) is a leading global provider of SaaS Source-to-Pay and Enterprise Contract Lifecycle Management (ECLM) solutions. The Determine Cloud Platform provides procurement, legal and finance professionals analytics of their supplier, contract and financial performance. Our technologies empower customers to drive new revenue, identify savings, improve compliance and mitigate risk.
The Determine Cloud Platform seamlessly integrates with major ERP or third-party systems such as SAP, Oracle, Sage, QAD and Microsoft. Modular solutions can be configured to add more as needed to provide additional value beyond spend management. Our unified master database and business process approach empower users at every level to make more informed and smarter decisions.
For more information, please visit: www.determine.com.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Determine, Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Stillfront Group AB: Stillfront one of Sweden's fastest growing companies19.10.2017 11:00 | Pressmeddelande
PRESS RELEASE October 19, 2017 Stillfront included in Deloitte Sweden Technology Fast 50 Stillfront has been included in Deloitte Sweden Technology Fast 50. Deloitte Sweden Technology Fast 50 is a ranking of Sweden's 50 fastest growing technology companies, based on revenue growth over the last four years. The ranking includes public and private companies, large and small, in all areas of technology, from internet specialists to biotech, digital media technology to life sciences, computers to semiconductors and software to telecommunications. Please find more detailed information (in Swedish) on www.deloitte.se/fast50. Stillfront has since the IPO in the autumn of 2015 recorded a continuous high and profitable growth in revenues rolling 12 months. Since the IPO, Stillfront has increased the number of so-called core products (i.e. games that have more than 5 MSEK in annual revenue rate) from four to fourteen and the number of studi
Stillfront Group AB: Stillfront ett av Sveriges snabbast växande teknikföretag19.10.2017 11:00 | Pressmeddelande
PRESSMEDDELANDE 2017-10-19 Stillfront med i Deloitte Sweden Technology Fast 50 Stillfront har kommit med i Deloitte Sweden Technology Fast 50 2017. Deloitte Sweden Technology Fast 50 är en ranking av Sveriges 50 snabbast växande teknologiföretag, baserat på tillväxten i nettoomsättningen de senaste fyra åren. Rankingen inkluderar såväl publika som privata bolag och omfattar all typ av teknologi, från mjuk- och hårdvara till life science, kommunikation och clean technology. Mer information finns på: www.deloitte.se/fast50. Stillfront har sedan noteringen hösten 2015 varje kvartal uppvisat en kontinuerlig hög och lönsam intäktstillväxt rullande 12 månader. Stillfront har sedan noteringen ökat antalet så kallade kärnprodukter (dvs spel som omsätter mer än 5 MSEK i årstakt) från fyra till fjorton och antalet studios har ökat från fyra till åtta. "Stillfront har åtnjutit en enastående tillväxt de senaste åren. Vår tillväxt bygger på vår s
Payvision's annual report reveals cross-border ecommerce trends in 201719.10.2017 09:00 | Pressmeddelande
With online marketplaces and consumer technology leading the way for growth AMSTERDAM, The Netherlands, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Payvision, global acquirer and data-driven omnichannel solutions provider, has published the findings of its fifth annual cross-border ecommerce research report, in collaboration with Juniper Research. The paper includes the results of a global survey of various industry players regarding the game-changers, the biggest challenges, the best practices for going cross-border, and much more. When compared to last year's findings, the report reveals a new and exciting context for global cross-border trade. The compound annual growth rate predicted for the next three years for cross-border ecommerce is now 17%, whereas it stands at just 12% for ecommerce overall. Also, over the past 12 months, merchants' attitudes towards cross-border ecommerce have become more positive, with 50% of respondents agreeing and 31% strongly
High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds19.10.2017 08:00 | Pressmeddelande
Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for more effective antiepileptic treatments EMERYVILLE, Calif. and BREST, France, Oct. 19, 2017 (GLOBE NEWSWIRE) -- The Dravet Syndrome European Federation and Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, announced today the publication of the initial results from a landmark survey into the clinical, social and economic consequences of Dravet syndrome on children, young adults and their families in Developmental Medicine & Child Neurology [doi:10.1111/dmcn.13591]. This study was led by Lieven Lagae, M.D., Ph.D., Professor at the University of Leuven, Belgium, Head of the Pediatric Neurology Department and Director of the Childhood Epilepsy
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53 | Pressmeddelande
AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc
Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42 | Pressmeddelande
NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum